JP2001513504A5 - - Google Patents

Download PDF

Info

Publication number
JP2001513504A5
JP2001513504A5 JP2000506973A JP2000506973A JP2001513504A5 JP 2001513504 A5 JP2001513504 A5 JP 2001513504A5 JP 2000506973 A JP2000506973 A JP 2000506973A JP 2000506973 A JP2000506973 A JP 2000506973A JP 2001513504 A5 JP2001513504 A5 JP 2001513504A5
Authority
JP
Japan
Prior art keywords
carrier
group
pharmaceutically acceptable
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000506973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001513504A (ja
JP4335435B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA1998/000744 external-priority patent/WO1999007383A1/en
Publication of JP2001513504A publication Critical patent/JP2001513504A/ja
Publication of JP2001513504A5 publication Critical patent/JP2001513504A5/ja
Application granted granted Critical
Publication of JP4335435B2 publication Critical patent/JP4335435B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000506973A 1997-08-05 1998-08-05 細胞増殖および細胞死を調節する組成物および方法 Expired - Fee Related JP4335435B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5477797P 1997-08-05 1997-08-05
US60/054,777 1997-08-05
US7511198P 1998-02-18 1998-02-18
US7506798P 1998-02-18 1998-02-18
US60/075,067 1998-02-18
US60/075,111 1998-02-18
US8631798P 1998-05-21 1998-05-21
US60/086,317 1998-05-21
PCT/CA1998/000744 WO1999007383A1 (en) 1997-08-05 1998-08-05 Composition and method for regulating cell proliferation and cell death

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008124958A Division JP2008208140A (ja) 1997-08-05 2008-05-12 細胞増殖および細胞死を調節する組成物および方法

Publications (3)

Publication Number Publication Date
JP2001513504A JP2001513504A (ja) 2001-09-04
JP2001513504A5 true JP2001513504A5 (enExample) 2008-08-21
JP4335435B2 JP4335435B2 (ja) 2009-09-30

Family

ID=27489673

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000506973A Expired - Fee Related JP4335435B2 (ja) 1997-08-05 1998-08-05 細胞増殖および細胞死を調節する組成物および方法
JP2008124958A Withdrawn JP2008208140A (ja) 1997-08-05 2008-05-12 細胞増殖および細胞死を調節する組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008124958A Withdrawn JP2008208140A (ja) 1997-08-05 2008-05-12 細胞増殖および細胞死を調節する組成物および方法

Country Status (17)

Country Link
US (2) US6329347B1 (enExample)
EP (1) EP1003525B1 (enExample)
JP (2) JP4335435B2 (enExample)
KR (1) KR100533576B1 (enExample)
AT (1) ATE227996T1 (enExample)
AU (1) AU736450B2 (enExample)
BR (1) BR9815602A (enExample)
CA (1) CA2299548C (enExample)
DE (1) DE69809561T2 (enExample)
DK (1) DK1003525T3 (enExample)
ES (1) ES2187047T3 (enExample)
HU (1) HU227921B1 (enExample)
IL (3) IL134371A0 (enExample)
NO (1) NO322450B1 (enExample)
NZ (1) NZ502674A (enExample)
PT (1) PT1003525E (enExample)
WO (1) WO1999007383A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2187047T3 (es) 1997-08-05 2003-05-16 Bioniche Life Sciences Inc Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular.
AU751667B2 (en) * 1998-02-18 2002-08-22 Bioniche Urology Ip Inc. Composition and method for the treatment of bladder cancer
CA2353905C (en) * 1998-12-04 2010-06-22 Nigel C. Phillips Chemotherapeutic composition and method
JP4488626B2 (ja) * 1998-12-04 2010-06-23 バイオニケ ライフ サイエンシーズ インコーポレイテッド 炎症の治療法
US6809081B1 (en) * 1998-12-04 2004-10-26 Bioniche Life Sciences, Inc. Chemotherapeutic composition and method
EP1165106B8 (en) * 1999-04-01 2005-07-27 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells by m-dna and mcc
US6794368B1 (en) 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
ATE375358T1 (de) 1999-04-08 2007-10-15 Antisoma Res Ltd Antiproliferative aktivität von g-reichen oligonukleotiden und verfahren um sie zur bindung an nukleotin zu verwenden
AU7501700A (en) * 1999-09-29 2001-04-30 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
EP1238070B1 (en) * 1999-12-13 2007-08-15 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
JP4215429B2 (ja) * 1999-12-28 2009-01-28 バイオニケ ライフ サイエンシーズ インコーポレイテッド 癌治療におけるヒアルロン酸
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US6673566B1 (en) 2002-01-10 2004-01-06 The United States Of America As Represented By The Secretary Of Agriculture Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes
EP2043616B1 (en) 2006-07-25 2016-01-27 Lipoxen Technologies Limited N-terminal conjugation of polysialic acid to proteins
ES2829416T3 (es) * 2010-10-13 2021-05-31 Telesta Therapeutics Inc Composiciones de pared celular del ácido ribonucleico bacteriano y procedimientos para prepararlas y usarlas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
FR2160326B1 (enExample) 1971-11-19 1975-02-07 Anvar
US4152423A (en) 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
US4010257A (en) 1973-02-23 1977-03-01 Burroughs Wellcome Co. Biological extracts
US3976544A (en) 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
JPH08508976A (ja) 1993-01-29 1996-09-24 ベトレフアーム・インコーポレーテツド 改善化免疫療法用組成物
ES2187047T3 (es) 1997-08-05 2003-05-16 Bioniche Life Sciences Inc Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular.

Similar Documents

Publication Publication Date Title
JP2001513504A5 (enExample)
JP2000507362A5 (enExample)
SG113402A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP0000714A3 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
DE69928260D1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
CA2153856A1 (en) Duloxetine enteric pellets
CA2427815A1 (en) Controlled release hydrocodone formulations
USD438297S1 (en) Deodorizing apparatus for personal use
CA2232450A1 (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
HUP0101434A3 (en) Sulfonamide-containing indole compounds, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing the same
JP2003520017A5 (enExample)
WO2001041737A3 (en) Solid oral dosage form
GB0117095D0 (en) "Process for the preparation of pure citalopram"
CA2163837A1 (en) Crystalline Paclitaxel Hydrates
HUP0200386A3 (en) Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity and pharmaceutical compositions containing them and their use
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
IT1293281B1 (it) Metodo ed unita' per il trasferimento, con ribaltamento, di pacchetti di sigarette.
CA2256751A1 (fr) Comprime enrobe a base de maleate de trimebutine
WO2001035940A3 (en) Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
USD416281S (en) Type font
FR2703995B1 (fr) 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
IT1286496B1 (it) Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
CA2185242A1 (en) Sustained release tablet containing diclofenac-na
JPH10237071A5 (enExample)